BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Buy Stocks for June 4th
BCRX, OPRX, BWB, PLMR and RACE have been added to the Zacks Rank #1 (Strong Buy) List on June 4, 2025.
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade
The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Best Momentum Stocks to Buy for May 9th
BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025.
New Strong Buy Stocks for May 9th
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.
Why BioCryst (BCRX) Might be Well Poised for a Surge
BioCryst (BCRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?
The mean of analysts' price targets for BioCryst (BCRX) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioCryst: Strong Opportunity For A Double With A Proven Therapy
BioCryst Pharmaceuticals' flagship product ORLADEYO shows remarkable growth, maintaining a persistent upward trajectory since its launch in 2020, and is expected to continue into 2025. Despite heavy reliance on ORLADEYO, BCRX stock remains a "Buy" due to its strong market presence and growth potential in the hereditary angioedema therapy market. The 10-K report highlights competition, including late-stage therapies and an upcoming PDUFA date for KalVista's sebetralstat, which could impact market dynamics.
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1
BioCryst Pharmaceuticals (BCRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago.
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
